News

This page includes recent news and media from all across the Hongsen Investment network.

February 12, 2025 Abcuro Announces $200 Million Series C Financing to Advance Its First-In-Class Medicine in Development for Inclusion Body Myositis

January 15, 2025 Eli Lilly pushes into pulmonary fibrosis with $99M deal for Mediar’s midphase prospect

January 10, 2025 Mediar Therapeutics Enters into Global Licensing Agreement with Lilly to Advance First-in-Class WISP1 Antibody for the Treatment of Idiopathic Pulmonary Fibrosis (IPF)

December 10, 2024 Skyhawk Receives Australian Regulatory Approval to Extend SKY-0515 Treatment Duration in Phase 1 Huntington's Disease Patient Trial

November 21, 2024 Skyhawk Therapeutics to Present Preclinical Data of SKY-1214 Combination Treatment in Hematologic Cancers at the 66th American Society of Hematology Annual Meeting

November 5, 2024 Obsidian Therapeutics to Present Preclinical Data Supporting OBX-115 and cytoDRiVE® Platform at the Society for Immunotherapy of Cancer (SITC) Annual Meeting 2024

October 24, 2024 Skyhawk Therapeutics Presents Compelling Preclinical Data on SKY-1214 at the EORTC-NCI-AACR Molecular Targets and Cancer Therapeutics Symposium

October 23, 2024 Circle Pharma’s First-in-Class Oral Macrocycle Cyclin A/B RxL Inhibitor, CID-078, Preclinical Data Highlighted at the 36th EORTC-NCI-AACR Symposium

October 15, 2024 Circle Pharma announces first patients dosed in Phase 1 clinical trial of first-in-class oral Cyclin A/B RxL inhibitor
CID-078 for advanced solid tumors

October 9, 2024 Boehringer Ingelheim and Circle Pharma announce new research collaboration to develop a novel precision cancer treatment

September 29, 2024 林普利塞片荣获“2024年上海市高新技术成果转化项目百佳”荣誉称号

September 11, 2024 Skyhawk Therapeutics to Present Additional Positive Topline Data from Parts A and B of Phase 1 Clinical Trial of SKY-0515 at European Huntington's Disease Network and Enroll-HD 2024

September 9, 2024 Circle Pharma announces preclinical data poster presentation of CID-078, a first-and-only-in-class Cyclin A/B RxL inhibitor at the 2024 World Conference on Lung Cancer

September 3, 204 Circle Pharma Closes $90 Million Series D Financing to Advance Innovative Oral Macrocycle Therapies

September 3, 2024 Obsidian Therapeutics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for OBX-115 for the Treatment of Advanced Melanoma

July 10, 2024 Skyhawk Therapeutics Announces Positive Topline Results of SKY-0515 as a Treatment for Huntington’s Disease, Reaching 72% Huntingtin mRNA Reduction

July 9, 2024 Obsidian Therapeutics Announces FDA Fast Track Designation for OBX-115 for the Treatment of Advanced Melanoma

July 1, 2024 Circle Pharma files first Investigational New Drug application for first-in-class oral cyclin A/B RxL inhibitor for treatment of advanced solid tumors

July 1, 2024 Skyhawk Therapeutics Expands into State-of-the-Art Labs in its Basel, Switzerland Location

June 25, 2024 Abcuro Completes Enrollment of Registrational Phase 2/3 MUSCLE Clinical Trial of Ulviprubart for the Treatment of Inclusion Body Myositis

June 4, 2024 Obsidian Therapeutics Announces Appointment of William Pao, M.D., Ph.D., to Board of Directors

May 8, 2024 Obsidian Therapeutics Appoints Dana Alexander as Chief Technical Officer

April 23, 2024 Ipsen, Skyhawk ink deal worth up to $1.8B

April 22, 2024 Ipsen and Skyhawk Therapeutics announce RNA targeting research collaboration in rare neurological diseases

April 22, 2024 Ipsen dives into $1.8B Skyhawk pact to fire up RNA modulator R&D

April 15, 2024 Obsidian Therapeutics Appoints Jeffrey Trigilio as Chief Financial Officer

April 9, 2024 Median Study Follow-Up Safety and Efficacy Data from First-in-Human Study of OBX-115 in Advanced Melanoma at the American Association for Cancer Research Annual Meeting

April 3, 2024 Obsidian Therapeutics Announces Oversubscribed $160.5 Million Series C Financing to Drive OBX-115 Clinical Development

March 25, 2024 Skyhawk Has Advanced to Multiple Ascending Dose in it’s SKY-0515

March 22, 2024 璎黎药业首个联合开发合作项目-全球新靶点HIPK2抑制剂RLA-23174获得中国临床试验许可

March 5, 2024 Obsidian Therapeutics Announces Clinical & Preclinical Presentations at the American Association of Cancer Research Annual Meeting

December 12, 2023 Obsidian Therapeutics Announces Positive Interim Top-Line Clinical Data for OBX-115 Engineered TIL Cell Therapy in Advanced or Metastatic Melanoma Post-Anti-PD1 Therapy

December 6, 2023 Abcuro Appoints Mark Pruzanski, M.D., as Chairman of its Board of Directors

November 13, 2023 Abcuro Initiates Part B of Registrational Phase 2/3 MUSCLE Clinical Trial of Ulviprubart (ABC008) for the Treatment of Inclusion Body Myositis

October 25, 2023 Mediar Therapeutics Announces Clinical Candidates for Lead Fibrosis Programs, Strategic Collaborations and Key Leadership Addition

October 23, 2023 Compelling Data in Breast Cancer Treatment with First-In-Class Cyclin A/B Inhibitor Presented at 2023 AACR-NCI-EORTC International Conference

October 23, 2023 Skyhawk Therapeutics Receives HREC Approval for a Phase 1 Study of its SKY-0515 RNA-Targeting Small

August 17, 2023 Abcuro Announces $155 Million Oversubscribed Series B Financing to Further Advance Autoimmune Pipeline

July 19, 2023 Circle Pharma Achieves Major Milestone with the Selection of a Clinical Development Candidate Directly Inhibiting Cyclins A and B

May 31, 2023 Abcuro Completes Enrollment of Sentinel Cohort in Phase 2/3 Study of ABC008 for the Treatment of Inclusion Body Myositis

May 23, 2023 Obsidian Therapeutics Announces Dr. Madan Jagasia as Chief Executive Officer and Other Leadership Appointments

April 19, 2023 Circle Pharma’s first-in-class orally bioavailable macrocyclic cyclin A/B inhibitors highlighted in poster presentations at American Association for Cancer Research Annual Meeting

April 3, 2023 Abcuro Initiates Registrational Phase 2/3 Study of ABC008 for the Treatment of Inclusion Body Myositis

March 15, 2023 Mediar Therapeutics Announces $105 Million Financing to Advance Portfolio of First-in-Class Fibrosis Therapies

November 22, 2022 Morphic Announces Initiation of EMERALD-2 Phase 2b Clinical Trial of MORF-057 in Patients with Moderate-to-Severe Ulcerative Colitis

November 9, 2022 璎黎药业抗癌新药林普利塞获批上市

November 2, 2022 Morphic Announces Corporate Highlights and Financial Results for the Third Quarter 2022

October 27, 2022 Obsidian Therapeutics Announces Extension of Multi-Year Collaboration Agreement with Bristol Myers Squibb

October 25, 2022 Morphic Presents New Positive MORF-057 Phase 1 Data at American College of Gastroenterology Annual Meeting 2022

October 24, 2022 Morphic Announces Complete Enrollment of EMERALD-1 Main Cohort Ahead of Projections

October 10, 2022 Morphic Presents New Positive MORF-057 Phase 1 Data at UEG Week 2022

October 4, 2022 Abcuro Initiates Phase 1/2 Trial Evaluating ABC008 in Patients with T Cell Large Granular Lymphocytic Leukemia

September 21, 2022 Morphic Celebrates Foundational Integrin Research Published In Cell

August 3, 2022 Morphic Announces Corporate Highlights And Financial Results For The Second Quarter 2022

July 21, 2022 MD Anderson and Obsidian Therapeutics announce FDA Clearance of IND application for novel TIL therapy OBX-115

July 5, 2022 Skyhawk Announces Cooperation Agreement with Sanofi for Oncology and Immunology Targets

May 17, 2022 Obsidian Therapeutics to Present Significant Advancements to its Proprietary cytoDRiVE® Technology at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting 2022

May 4, 2022 Morphic Announces Corporate Highlights And Financial Results For The First Quarter 2022

April 11, 2022 Obsidian Therapeutics to Present Preclinical Data from cytoTIL15™ Program at the American Associate of Cancer Research (AACR) Annual Meeting 2022

April 11, 2022 Circle Pharma Announces Presentation at the American Associationfor Cancer Research 2022 Annual Meeting

February 22, 2022 Morphic Presents Positive MORF-057 Data In Oral Presentation At ECCO 2022

November 9, 2021 Obsidian Therapeutics to Present In Vivo Anti-TumorEfficacy Data from Novel Engineered cytoTIL15 Program at SITC 2021

November 5, 2021 Abcuro to Present Late-Breaking Abstract at American College of Rheumatology Convergence 2021 of ABC008 Inclusion Body Myositis Phase 1 Data Demonstrating Proof of Mechanism for Selective Depletion of Highly Cytotoxic T Cells

November 4, 2021 Morphic Announces Corporate Highlights And Third Quarter 2021 Financial Results

September 15, 2021 Obsidian Therapeutics To Present Preclinical Data From cytoTIL15 Program at the European Society for Medical Oncology Congress 2021

September 15, 2021 Simon Sturge Joins Mediar Therapeutics as Executive Chairman

September 10, 2021 璎黎药业获得NMPA抗肿瘤新药Linperlisib（YY-20394）突破性疗法认定

September 9, 2021 Obsidian Therapeutics Announces Closing of $115 Million Series B Financing

July 9. 2021 Morphic Reports New Data From Positive Phase 1 Study Of MORF-057, Oral Integrin Inhibitor Candidate For IBD

June 30, 2021 Abcuro and ImaginAb Share Initial Results of Study Using Novel Technology for Imaging T Cell Infiltration of Skeletal Muscle in Patients with Inclusion Body Myositis

June 16, 2021 Circle Pharma raises $66 Million in Series C Financing

April 29, 2021 Morphic Announces Corporate Highlights And First Quarter 2021 Financial Results

April 22, 2021 Vertex and Obsidian Therapeutics Establish Collaboration to Discover Novel Therapies That Regulate Gene Editing

April 12, 2021 Morphic Therapeutic Presents Preclinical Data From ΑVΒ8 Integrin Program At American Association For Cancer Research (AACR) Annual Meeting

March 30, 2021 上海璎黎药业PI3Kδ抑制剂Linperlisib治疗复发/难治滤泡性淋巴瘤2期注册临床结果喜人

March 17, 2021 Mediar Therapeutics Adds New Investors As It Advances Anti-Fibrotic Treatments

March 1, 2021 Morphic Reports Positive Interim Results From Single Ascending Dose Phase 1 Clinical Trial Of MORF-057

February 9, 2021 璎黎药业与恒瑞医药达成战略合作，共同开拓中国肿瘤市场

Feburary 2, 2021 璎黎药业完成数千万美元A轮融资

January 7, 2021 Abcuro Raises $42 Million in Series A-1 Financing, Appoints John B. Edwards as Executive Chair of the Board of Directors and David de Graaf, Ph.D. as Chief Executive Officer

January 6, 2021 $40M up front: Skyhawk takes flight with Vertex deal

January 5, 2021 Morphic Expands Research And Development Collaboration With Janssen Through Third Integrin Program

December 22, 2020 Vertex joins Skyhawk's roster of A-list partners, securing options on RNA splicing modulators

November 18, 2020 Obsidian Therapeutics & MD Anderson announce strategic collaboration to accelerate advancement of novel engineered tumor infiltrating lymphocyte therapy (cytoTIL™) for solid tumors

October 26, 2020 Circle Pharma Appoints James Aggen, PhD as Its Vice President, Medicinal Chemistry

October 21, 2020 Circle Pharma Appoints Alan Ashworth, PhD, FRS and Bruce Stillman, PhD, FRS to Its SAB

September 15, 2020 Obsidian Therapeutics Announces Bristol Myers Squibb Opt-In of cytoDRiVE™ Cell Therapy Candidate